Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
CHTP's Cash to Debt is ranked higher than
95% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. CHTP: No Debt )
CHTP' s 10-Year Cash to Debt Range
Min: 2.94   Max: No Debt
Current: No Debt

Interest Coverage No Debt
CHTP's Interest Coverage is ranked higher than
78% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CHTP: No Debt )
CHTP' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 64.29
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE (%) -37.95
CHTP's ROE (%) is ranked higher than
65% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. CHTP: -37.95 )
CHTP' s 10-Year ROE (%) Range
Min: -332.05   Max: -26.02
Current: -37.95

-332.05
-26.02
ROA (%) -35.30
CHTP's ROA (%) is ranked higher than
64% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. CHTP: -35.30 )
CHTP' s 10-Year ROA (%) Range
Min: -230.99   Max: -23.88
Current: -35.3

-230.99
-23.88
ROC (Joel Greenblatt) (%) -36520.00
CHTP's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. CHTP: -36520.00 )
CHTP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -38383.72   Max: -5860.78
Current: -36520

-38383.72
-5860.78
EBITDA Growth (%) -35.60
CHTP's EBITDA Growth (%) is ranked higher than
56% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. CHTP: -35.60 )
CHTP' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 194.3
Current: -35.6

0
194.3
EPS Growth (%) -35.90
CHTP's EPS Growth (%) is ranked higher than
59% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. CHTP: -35.90 )
CHTP' s 10-Year EPS Growth (%) Range
Min: 0   Max: 184.4
Current: -35.9

0
184.4
» CHTP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

CHTP Guru Trades in Q1 2013

Jim Simons 74,894 sh (New)
Chuck Royce 710,000 sh (unchged)
Columbia Wanger 4,302,458 sh (-46.4%)
» More
Q2 2013

CHTP Guru Trades in Q2 2013

Columbia Wanger Sold Out
Chuck Royce 630,000 sh (-11.27%)
Jim Simons 10,394 sh (-86.12%)
» More
Q3 2013

CHTP Guru Trades in Q3 2013

Jim Simons 225,695 sh (+2071.4%)
Chuck Royce 560,000 sh (-11.11%)
» More
Q4 2013

CHTP Guru Trades in Q4 2013

Paul Tudor Jones 20,895 sh (New)
Jim Simons 716,494 sh (+217.46%)
Chuck Royce 120,000 sh (-78.57%)
» More
» Details

Insider Trades

Latest Guru Trades with CHTP

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2011-09-30 Sold Out 0.0025%$3.56 - $5.89 $ 4.764%0
George Soros 2011-06-30 New Buy$3.83 - $5.34 $ 4.765%34800
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 8.70
CHTP's P/B is ranked lower than
57% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. CHTP: 8.70 )
CHTP' s 10-Year P/B Range
Min: 0   Max: 22
Current: 8.7

0
22
EV-to-EBIT 14.50
CHTP's EV-to-EBIT is ranked higher than
69% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. CHTP: 14.50 )
CHTP' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 14.5

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.80
CHTP's Price/Net Cash is ranked higher than
54% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. CHTP: 8.80 )
CHTP' s 10-Year Price/Net Cash Range
Min: 2   Max: 16.53
Current: 8.8

2
16.53
Price/Net Current Asset Value 8.80
CHTP's Price/Net Current Asset Value is ranked higher than
54% of the 525 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. CHTP: 8.80 )
CHTP' s 10-Year Price/Net Current Asset Value Range
Min: 2   Max: 16.53
Current: 8.8

2
16.53
Price/Tangible Book 8.70
CHTP's Price/Tangible Book is ranked lower than
58% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. CHTP: 8.70 )
CHTP' s 10-Year Price/Tangible Book Range
Min: 1.63   Max: 14.79
Current: 8.7

1.63
14.79
Forward Rate of Return (Yacktman) -40.36
CHTP's Forward Rate of Return (Yacktman) is ranked higher than
62% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. CHTP: -40.36 )
CHTP' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -40.36

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:3CH.Germany
Chelsea Therapeutics International, Ltd., is a specialty pharmaceutical company focused on the acquisition, development and commercialization of innovative pharmaceutical products. The Company's currently licensed compounds target a variety of prevalent medical conditions; particularly rheumatoid arthritis, psoriasis, cancer, other immunological disorders, neurogenic orthostatic hypotension and other autonomic disorders. The Company is developing droxidopa, an orally active synthetic precursor of norepinephrine and its investigational product candidate, for the treatment of neurogenic orthostatic hypotension (NOH). It is currently focusing the majority of its drug development resources on two clinical stage development projects: droxidopa for symptomatic neurogenic orthostatic hypotension and other potential indications; and its portfolio of non-metabolized antifolate compounds for the treatment of rheumatoid arthritis. Droxidopa, a synthetic amino acid, is converted by the body into norepinephrine and, as a prodrug of norepinephrine, provides replacement therapy for norepinephrine deficiency. Norepinephrine is both a hormone and a neurotransmitter. As a hormone, secreted by the adrenal gland, it works alongside epinephrine/adrenaline to give the body sudden energy in times of stress, known as the 'fight or flight' response. As a neurotransmitter, it passes nerve impulses from one neuron to the next. While norepinephrine, as a catecholamine does not penetrate the blood-brain barrier, droxidopa, as a neutral amino acid, is able to do so thus providing both a peripheral and central effect on circulating norepinephrine levels. The FDA and foreign regulatory agencies regulate many aspects of product development and marketing of its product candidates including research, development, manufacture, labeling, promotion, advertising, distribution, and marketing.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

Sonny anand
ReplySonny anand - 1 month ago
fda has approved wait for 3 years

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide